Electroporation-mediated administration of candidate DNA vaccines against HIV-1

Methods in Molecular Biology

Volumn 1121, Issue , 2014, Pages 291-307

  Vasan, Sandhya ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

DNA; Electroporation; HIV; Prevention; Vaccines

Indexed keywords

DNA VACCINE;

ARTICLE; DNA IMMUNIZATION; DRUG DEVELOPMENT; DRUG SCREENING; ELECTROPORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IN VIVO STUDY; MEDICAL TECHNOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINE PRODUCTION;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; ELECTROPORATION; HIV-1; HUMANS; VACCINES, DNA;

EID: 84934439933     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9632-8_26     Document Type: Article

References (122)

1. Barre-Sinoussi F, Chermann JC, Rey F et al (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune defi ciency syndrome (AIDS). Science 220:868-871
2. Gallo RC, Salahuddin SZ, Popovic M et al (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503
3. UNAIDS (2012) Report on the Global AIDS Epidemic. ISBN 978-92-9173-996-7
4. Miller CJ, Li Q, Abel K et al (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodefi ciency virus. J Virol 79:9217-9227
5. Spira AI, Marx PA, Patterson BK et al (1996) Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodefi ciency virus into rhesus macaques. J Exp Med 183:215-225
6. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223
7. Gaschen B, Taylor J, Yusim K et al (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360
8. Letourneau S, Im EJ, Mashishi T et al (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984
9. Liao HX, Sutherland LL, Xia SM et al (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-282
10. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF (2004) Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 3:S161-S168
11. Barouch DH, O'Brien KL, Simmons NL et al (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-323
12. Santra S, Liao HX, Zhang R et al (2010) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse hiv strains in monkeys. Nat Med 16:324-328
13. Ndhlovu ZM, Piechocka-Trocha A, Vine S et al (2011) Mosaic HIV-1 Gag antigens can be processed and presented to human HIVspecifi c CD8+ T cells. J Immunol 186:6914-6924
14. Jiang X, Burke V, Totrov M et al (2010) Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 17:955-961
15. Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, Cardozo T (2010) Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses 26:717-723
16. Schief WR, Ban YE, Stamatatos L (2009) Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4:431-440
17. Pejchal R, Doores KJ, Walker LM et al (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103
18. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H (2004) Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 20:755-762
19. Alam SM, McAdams M, Boren D et al (2007) The role of antibody polyspecifi city and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178:4424-4435
20. Deeks SG, Schweighardt B, Wrin T et al (2006) Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodefi-ciency virus (HIV) infection: evidence for a constraint on the ability of hiv to completely evade neutralizing antibody responses. J Virol 80:6155-6164
21. Dhillon AK, Donners H, Pantophlet R et al (2007) Dissecting the neutralizing antibody specifi cities of broadly neutralizing sera from human immunodefi ciency virus type 1-infected donors. J Virol 81:6548-6562
22. Doria-Rose NA, Klein RM, Manion MM et al (2009) Frequency and phenotype of human immunodefi ciency virus envelope-specifi c B cells from patients with broadly crossneutralizing antibodies. J Virol 83:188-199
23. Binley JM, Lybarger EA, Crooks ET et al (2008) Profi ling the specifi city of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodefi ciency virus type 1 subtypes B and C. J Virol 82:11651-11668
24. Gray ES, Taylor N, Wycuff D et al (2009) Antibody specifi cities associated with neutralization breadth in plasma from human immunodefi ciency virus type 1 subtype C-infected blood donors. J Virol 83:8925-8937
25. Simek MD, Rida W, Priddy FH et al (2009) Human immunodefi ciency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identifi ed by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83:7337-7348
26. Sather DN, Armann J, Ching LK et al (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodefi ciency virus type 1 infection. J Virol 83:757-769
27. Mouquet H, Scheid JF, Zoller MJ et al (2010) Polyreactivity increases the apparent affi nity of anti-HIV antibodies by heteroligation. Nature 467:591-595
28. Liao HX, Chen X, Munshaw S et al (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208:2237-2249
29. Haynes BF, Fleming J, St Clair EW et al (2005) Cardiolipin polyspecifi c autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908
30. Matyas GR, Beck Z, Karasavvas N, Alving CR (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 1788:660-665
31. Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC (2012) Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci USA 109:875-880
32. Ulmer JB, Donnelly JJ, Parker SE et al (1993) Heterologous protection against infl uenza by injection of DNA encoding a viral protein. Science 259:1745-1749
33. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175:633-639
34. Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108-120
35. Wang R, Doolan DL, Le TP et al (1998) Induction of antigen-specifi c cytotoxic t lymphocytes in humans by a malaria DNA vaccine. Science 282:476-480
36. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ (2003) Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21:4604-4608
37. Catanzaro AT, Roederer M, Koup RA et al (2007) Phase I clinical evaluation of a sixplasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25:4085-4092
38. Graham BS, Koup RA, Roederer M et al (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194:1650-1660
39. Rosati M, Bergamaschi C, Valentin A et al (2009) DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci USA 106:15831-15836
40. Fuller DH, Rajakumar PA, Wilson LA et al (2002) Induction of mucosal protection against primary, heterologous simian immunodefi ciency virus by a DNA vaccine. J Virol 76:3309-3317
41. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18:927-974
42. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997) DNA vaccines. Annu Rev Immunol 15:617-648
43. Nwanegbo E, Vardas E, Gao W et al (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11:351-357
44. Mast TC, Kierstead L, Gupta SB et al (2010) International epidemiology of human preexisting adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential hiv vaccine trials. Vaccine 28:950-957
45. Santra S, Seaman MS, Xu L et al (2005) Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79:6516-6522
46. Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgonne H, Kimman TG (2006) Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2:45-53
47. Mulligan MJ, Russell ND, Celum C et al (2006) Excellent safety and tolerability of the human immunodefi ciency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in hiv type 1 uninfected adults. AIDS Res Hum Retroviruses 22:678-683
48. Gorse GJ, Baden LR, Wecker M et al (2008) Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodefi ciency virus type 1 (HIV-1)-uninfected adults. Vaccine 26:215-223
49. Jaoko W, Nakwagala FN, Anzala O et al (2008) Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid p THr DNA or modifi ed vaccinia virus Ankara (mva) in humans in East Africa. Vaccine 26:2788-2795
50. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776-788
51. Amara RR, Villinger F, Altman JD et al (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/mva vaccine. Science 292:69-74
52. McConkey SJ, Reece WH, Moorthy VS et al (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modifi ed vaccinia virus Ankara in humans. Nat Med 9:729-735
53. Harari A, Bart PA, Stohr W et al (2008) An HIV-1 clade c DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205:63-77
54. Goonetilleke N, Moore S, Dally L et al (2006) Induction of multifunctional human immunodefi ciency virus type 1 (HIV-1)-specifi c T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-And modifi ed vaccinia virus Ankaravectored vaccines expressing HIV-1 GAG coupled to CD8+ T-cell epitopes. J Virol 80:4717-4728
55. Wang S, Kennedy JS, West K et al (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:3947-3957
56. Lu S (2008) Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 4:449-452
57. Zolla-Pazner S, Kong XP, Jiang X et al (2011) Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol 85:9887-9898
58. Manam S, Ledwith BJ, Barnum AB et al (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43:273-281
59. Manoj S, Babiuk LA, van Drunen Littel-van den Hurk S (2004) Approaches to enhance the effi cacy of DNA vaccines. Crit Rev Clin Lab Sci 41:1-39
60. Mathiesen I (1999) Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6:508-514
61. Widera G, Austin M, Rabussay D et al (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164:4635-4640
62. Babiuk S, Baca-Estrada ME, Foldvari M et al (2004) Increased gene expression and infl ammatory cell infi ltration caused by electroporation are both important for improving the effi cacy of DNA vaccines. J Biotechnol 110:1-10
63. Liu J, Kjeken R, Mathiesen I, Barouch DH (2008) Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodefi ciency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 82:5643-5649
64. Babiuk S, Baca-Estrada ME, Foldvari M et al (2002) Electroporation improves the effi cacy of DNA vaccines in large animals. Vaccine 20:3399-3408
65. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R (2006) Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24:4490-4493
66. Li Z, Zhang H, Fan X et al (2006) DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24:4565-4568
67. Hooper JW, Golden JW, Ferro AM, King AD (2007) Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25:1814-1823
68. Dobano C, Widera G, Rabussay D, Doolan DL (2007) Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 25:6635-6645
69. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D (2010) Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28:1056-1061
70. Chen MW, Cheng TJ, Huang Y et al (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 infl uenza viruses. Proc Natl Acad Sci USA 105:13538-13543
71. LeBlanc R, Vasquez Y, Hannaman D, Kumar N (2008) Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmissionblocking vaccine by in vivo electroporation. Vaccine 26:185-192
72. Bodles-Brakhop AM, Draghia-Akli R (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7:1085-1101
73. Best SR, Peng S, Juang CM et al (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27:5450-5459
74. Dupuis M, Denis-Mize K, Woo C et al (2000) Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 165:2850-2858
75. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J (2000) Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 83:147-152
76. Uno-Furuta S, Tamaki S, Takebe Y et al (2001) Induction of virus-specifi c cytotoxic T lymphocytes by in vivo electric administration of peptides. Vaccine 19:2190-2196
77. Otten G, Schaefer M, Doe B et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489-2493
78. Otten GR, Schaefer M, Doe B et al (2006) Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24:4503-4509
79. Luckay A, Sidhu MK, Kjeken R et al (2007) Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccinespecifi c immune responses in rhesus macaques. J Virol 81:5257-5269
80. Kulkarni V, Jalah R, Ganneru B et al (2011) Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 29:6742-6754
81. Dolter KE, Evans CF, Ellefsen B et al (2011) Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 29:795-803
82. Simon AJ, Casimiro DR, Finnefrock AC et al (2008) Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates. Vaccine 26:5202-5209
83. Yin J, Dai A, Lecureux J et al (2011) High antibody and cellular responses induced to HIV-1 clade c envelope following DNA vaccines delivered by electroporation. Vaccine 29:6763-6770
84. Cristillo AD, Galmin L, Restrepo S et al (2008) HIV-1 Env vaccine comprised of electroporated DNA and protein co-Administered with talabostat. Biochem Biophys Res Commun 370:22-26
85. Hirao LA, Wu L, Khan AS et al (2008) Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26:3112-3120
86. Muthumani G, Laddy DJ, Sundaram SG et al (2009) Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specifi c CD8 T cells. Immunology 128:e612-e620
87. Kraynyak KA, Kutzler MA, Cisper NJ, et al (2011) Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine 28:1942-1951
88. Belisle SE, Yin J, Shedlock DJ et al (2011) Long-term programming of antigen-specifi c immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS One 6:e19681
89. Law M, Cardoso RM, Wilson IA, Burton DR (2007) Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 81:4272-4285
90. Cristillo AD, Weiss D, Hudacik L et al (2008) Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 366:29-35
91. Winstone N, Wilson AJ, Morrow G et al (2011) Enhanced control of pathogenic Simian immunodefi ciency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 85:9578-9587
92. Knudsen ML, Mbewe-Mvula A, Rosario M et al (2012) Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J Virol 86:4082-4090
93. Rosario M, Borthwick N, Stewart-Jones GB et al (2012) Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 26:275-284
94. Hutnick NA, Myles DJ, Hirao L et al (2012) An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine 30:3202-3208
95. Hallengard D, Applequist SE, Nystrom S, et al (2012) Immunization with multiple vaccine modalities induce strong HIV-specifi c cellular and humoral immune responses. Viral Immunol 25:423-432
96. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB (2008) Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26:440-448
97. Martinon F, Kaldma K, Sikut R et al (2009) Persistent immune responses induced by a human immunodefi ciency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther 20:1291-1307
98. Brave A, Gudmundsdotter L, Sandstrom E et al (2010) Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 28:8203-8209
99. Brave A, Nystrom S, Roos AK, Applequist SE (2011) Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses. Immunol Cell Biol 89:492-496
100. Hallengard D, Haller BK, Maltais AK et al (2011) Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol 18:1577-1581
101. Hutnick NA, Myles DJ, Ferraro B et al (2012) Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther 23: 943-950
102. Lin F, Shen X, Kichaev G et al (2012) Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods 23:157-168
103. Roos AK, Eriksson F, Timmons JA et al (2009) Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 4:e7226
104. Lin F, Shen X, McCoy JR et al (2011) A novel prototype device for electroporationenhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29:6771-6780
105. Rosati M, Valentin A, Jalah R et al (2008) Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26:5223-5229
106. Valentin A, von Gegerfelt A, Rosati M et al (2010) Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefi t. Vaccine 28:1962-1974
107. van Drunen Littel-van den Hurk S, Hannaman D (2010) Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 9:503-517
108. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M (2008) Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34:232-240
109. Stevenson FK, Ottensmeier CH, Johnson P et al (2004) DNA vaccines to attack cancer. Proc Natl Acad Sci USA 101(Suppl 2):14646-14652
110. Low L, Mander A, McCann K et al (2009) DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20:1269-1278
111. Chudley L, McCann K, Mander A et al (2012) DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 61:2161-2170
112. Yang FQ, Yu YY, Wang GQ et al (2012) A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 19:581-593
113. Cellectis Bioresearch, Inc. http://www.cellectis. com/dermavax
114. Luxembourg A, Evans CF, Hannaman D (2007) Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 7:1647-1664
115. Vasan S, Hurley A, Schlesinger SJ et al (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6(5):e19252, by permission of PLOS One/Creative Commons Attribution License
116. Huang Y, Chen Z, Zhang W et al (2008) Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J Acquir Immune Defi c Syndr 47:403-411
117. Kopycinski J, Cheeseman H, Ashraf A et al (2012) A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol 19:1557-1559
118. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220
119. Haynes BF, Gilbert PB, McElrath MJ et al (2012) Immune-correlates analysis of an HIV-1 vaccine effi cacy trial. N Engl J Med 366:1275-1286
120. www.clinicaltrials.gov
121. Currier JR, Ngauy V, de Souza MS et al (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modifi ed vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5:e13983
122. Keefer MC, Gilmour J, Hayes P et al (2012) A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 7:e41936